La Jolla Pharmaceutical Company (LJPC) 2018年年度报告「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2018ORo TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For t

2、he transition period from toCommission file number:1-36282 LA JOLLA PHARMACEUTICAL COMPANY(Exact name of registrant as specified in its charter)California 33-0361285(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification Number)4550 Towne Centre Court,San Diego,C

3、A 92121(Address of principal executive offices,including Zip Code)Registrants telephone number,including area code:(858)207-4264Securities registered pursuant to Section 12(b)of the Act:Title of each class Name of each exchange on which registeredCommon Stock,Par Value$0.0001 per share The Nasdaq Ca

4、pital MarketSecurities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes o No xIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 o

5、r 15(d)of the Securities Act.Yes o No xIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12months(or for such shorter period that the registrant was required to file such report

6、s),and(2)has been subject to the filing requirements for the past 90 days.Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 ofthis chapter)during the preceding 12 mo